Foto del docente

Margherita Nannini

Ricercatrice a tempo determinato tipo a) (junior)

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale

Settore scientifico disciplinare: MED/06 ONCOLOGIA MEDICA

Curriculum vitae

Dott.ssa Margherita Nannini

Ricercatore a tempo determinato presso il Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale

Istituto di Ematologia e scienze Oncologiche “L. e A. Seràgnoli”
Via Massarenti, 9 - 40138 Bologna - Italy
Tel. +39/051/6363680
Fax +39/051/6364037
e-mail: margherita.nannini@unibo.it

Nata a Bologna, Italia, il 17/05/1982


Esperienza professionale

Medico specialista in Oncologia presso l'istituto di Ematologia ad Oncologia Medica “L.A. Seragnoli”, S. Orsola Malpighi, Università di Bologna - Dipartimento di Medicina specialistica, diagnostica e sperimentale (DIMES) dell'Università di Bologna

 

Dal 1 Agosto 2014: Ricercatore a tempo determinato presso il Dipartimento di Medicina specialistica, diagnostica e sperimentale (DIMES) dell'Università di Bologna - Titolo del programma di ricerca triennale: Biologia e trattamento su base molecolare dei tumori rari come modello clinico in oncologia medica


Istruzione e formazione

Dal 1 Novembre 2012 al 31 Luglio 2014: Assegnista di ricerca presso il Dipartimento di Medicina specialistica, diagnostica e sperimentale (DIMES) dell'Università di Bologna - Titolo del progetto: Gestione multidisciplinare dei tumori gastrointestinali, dei carcinomi renali, dei sarcomi e neoplasie ad alta complessità

 

30 Ottobre 2012: Medico specialista in Oncologia presso l'Università di Bologna - Titolo della tesi: Analisi genomica dei tumori stromali gastrointestinali (GIST) wild-type (WT) con approccio di next generation sequencing

 

Febbraio 2008: Esame di Stato di Abilitazione all'esercizio della professione di Medico

 

11 Giugno 2007: Laurea in Medicina e Chirurgia (110/110L) presso l'Università di Bologna - Titolo della tesi: Studio del profilo di espressione genica delle metastasi epatiche da cancro del colon-retto”

 

14 Luglio 2001: Diploma Liceo Classico (100/100) presso il Liceo Ginnasio Statale “L. Galvani”, Bologna

 

Incarico istituzionale

Docente referente (Università di Bologna) nell'ambito degli accordi bilaterali LL/ERASMUS con la Semmelweis University (Ungheria) e la Poznan University Medical School (Polonia) (dal 2017)

 

Membership

  • Membro del GISTStudyGroup e SarcomaStudyGroup di Bologna
  • Membro dell'Italian Sarcoma Group (ISG)
  • Membro dell'ESMO

 

Principali progetti di ricerca

Tumori stromali gastrointestinali (GIST)

Sarcomi viscerali del retroperitoneo

 

Relatore ai seguenti meeting scientifici:


GIST E TUMORI RARI: PERCORSO DIAGNOSTICO-TERAPEUTICO NELLA PRATICA CLINICA (Palermo, 3-4 Aprile 2012): Highlights: GIST le mutazioni oltre c-kit e PDGFRA

GASTRO IN 2012 (Firenze, 24-25 Settembre 2012): Tumori Stromali Gastrointestinali (GIST)

ARCHEOLOGIST Summit 2013 (Prague, 14-15 Maggio 2013): Tailoring therapy with sunitinib in a elderly patient with advanced GIST

XVIII RIUNIONE ANNUALE ITALIAN SARCOMA GROUP (Padova, 7-8 Aprile 2014): Novità nel 2014: analisi mutazionale di KIT/PDGFRA sul sangue periferico

GIST, dalle evidenze scientifiche alla pratica clinica (Bologna, 11 Aprile 2014): PDTA GIST e sarcomi addominali: un'esperienza da esportare

 XIX RIUNIONE ANNUALE ITALIAN SARCOMA GROUP (Firenze, 10-11 Aprile 2015): GIST: novità in tema di biologia molecolare

1° Congresso Nazionale IART (Cremona 7 e 8 maggio 2015): GIST: Basi molecolari della terapia a bersaglio molecolare

GIST, PERCORSO DIAGNOSTICO-TERAPEUTICO NELLA PRATICA CLINICA (Bologna, 17 MARZO 2016): Terapia medica e trattamenti loco-regionali nei GIST: un approccio integrato

Il POLICLINICO S.ORSOLA-MAPIGHI DìIN EUROPA RIFERIMENTO PER I TUMORI RARI (Bologna, 27 SETTEMBRE 2017): L'importanza dei centri di riferimento nei GIST

 

Premi conseguiti:

Conseguimento del premio come miglior caso clinico presentato all'ARCHEOLOGIST Summit 2013 che si tenuto a Praga in data 14-15 Maggio 2013.


Principali clinical trials a cui ho partecipato come sub-investigator:

Con esperienza nella sperimentazione secondo le Norme di Good Clinical Practice (GCP):

 

Pfizer A6181112: A phase IIIB, randomized, active, controller open-label study of SUNITINIB (SUTENT) 37.5 mg dailiy vs Imatinib Mesylate 800 mg daily in the treatment of patients with Gastrointestinal Stromal Tumors (GIST) who have had progressive disease while on 400 mg daily of Imatinib

 

A randomized, open-label, multi-center study to evaluate the efficacy of nilotinib versus best supportive care with or without a tyrosine kinase inhibitor (investigator's chioice) in adult patients with gastrointetsinal stromal tumors resistant to both imatinib and sunitinib 

 

A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST)

 

A dose-finding phase Ib multicenter study of imatinib in combination with the oral phosphatidyl-inositol 3-kinase (PI3K) inhibitor BTL719 in patients with gastrointestinal stromal tumor (GIST) who failed prior therapy with imatinib and sunitinib.

 

Pubblicazioni:

  1. Ravegnini G, Sammarini G, Nannini M, Pantaleo MA, Biasco G, Hrelia P, Angelini S. Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis. Autophagy. 2017 Mar 4;13(3):452-463
  2. Nannini M, Urbini M, Astolfi A, Biasco G, Pantaleo MA. The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST). J Transl Med. 2017 May 23;15(1):113.
  3. De Simone B, Ansaloni L, Sartelli M, Coccolini F, Di Saverio S, Pantaleo MA, Saponara M, Nannini M, Abongwa HK, Napoli JA, Catena F. What is changing in the surgical treatment of gastrointestinal stromal tumors after multidisciplinary approach? A comprehensive literature's review. Minerva Chir. 2017 Feb 14
  4. Ravegnini G, Nannini M, Zenesini C, Simeon V, Sammarini G, Urbini M, Gatto L,Saponara M, Biasco G, Pantaleo MA, Venturoli N, Hrelia P, Angelini S. An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure. Angiogenesis. 2017 Feb;20(1):139-148.
  5. Pantaleo MA, Urbini M, Indio V, Ravegnini G, Nannini M, De Luca M, Tarantino G, Angelini S, Gronchi A, Vincenzi B, Grignani G, Colombo C, Fumagalli E, Gatto L, Saponara M, Ianni M, Paterini P, Santini D, Pirini MG, Ceccarelli C, AltimariA, Gruppioni E, Renne SL, Collini P, Stacchiotti S, Brandi G, Casali PG, Pinna AD, Astolfi A, Biasco G. Genome-wide Analyses Identifies MEN1 and MAX Mutation and a Neuroendocrine-like Molecular Heterogeneity in Quadruple WT GIST. Mol Cancer Res. 2017 [Epub ahead of print]
  6. Gatto L, Nannini M, Saponara M, Di Scioscio V, Beltramo G, Frezza GP, Ercolani G, Pinna AD, Astolfi A, Urbini M, Brandi G, Biasco G, Pantaleo MA. Radiotherapy in the management of gist: state of the art and new potential scenarios. Clin Sarcoma Res. 2017 Jan 10;7:1.
  7. Ravegnini G, Nannini M, Simeon V, Musti M, Sammarini G, Saponara M, Gatto L, Urbini M, Astolfi A, Biasco G, Pantaleo MA, Venturoli N, Hrelia P, Angelini S. Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.Tumour Biol. 2016 Jul 27. [Epub ahead of print]
  8. Pantaleo MA, Nannini M. Long-term outcome of molecular subgroups of gastrointestinal stromal tumour patients treated with standard-dose imatinib in the BFR14 trial: The wild-type gastrointestinal stromal tumours are not a single group yet. Eur J Cancer. 2016 Feb 28;58:38-40.
  9. Saponara M, Urbini M, Astolfi A, Indio V, Ercolani G, Del Gaudio M, Santini D, Pirini MG, Fiorentino M, Nannini M, Lolli C, Mandrioli A, Gatto L, Brandi G, Biasco G, Pinna AD, Pantaleo MA. Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS). Oncotarget. 2015 Dec 8;6(39):42243-57.
  10. Astolfi A, Urbini M, Indio V, Nannini M, Genovese CG, Santini D, Saponara M, Mandrioli A, Ercolani G, Brandi G, Biasco G, Pantaleo MA. Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST). BMC Genomics. 2015 Nov 3;16:892.
  11. Nannini M, Ravegnini G, Angelini S, Astolfi A, Biasco G, Pantaleo MA. miRNA profiling in gastrointestinal stromal tumors: implication as diagnostic and prognostic markers. Epigenomics. 2015 Sep;7(6):1033-49.
  12. Vincenzi B, Nannini M, Fumagalli E, Bronte G, Frezza AM, De Lisi D, Spalato Ceruso M, Santini D, Badalamenti G, Pantaleo MA, Russo A, Dei Tos AP, Casali P, Tonini G. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. Oncotarget. 2015 Sep 24 [Epub ahead of print].
  13. Urbini M, Astolfi A, Indio V, Heinrich MC, Corless CL, Nannini M, Ravegnini G, Biasco G, Pantaleo MA. SDHC methylation in gastrointestinal stromal tumors (GIST): a case report. BMC Med Genet. 2015 Sep 28;16:87.
  14. Minichillo S, Pantaleo MA, Nannini M, Coccolo F, Gatto L, Biasco G, Brandi G. Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma. BMC Res Notes. 2015 Jul 30;8:325.
  15. Ravegnini G, Nannini M, Sammarini G, Astolfi A, Biasco G, Pantaleo MA, Hrelia P, Angelini S. Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis. Int J Mol Sci. 2015 Jul 9;16(7):15592-608.
  16. Nannini M, Biasco G, Pantaleo MA; The GIST Study Group, Bologna. An immunohistochemical study of potential diagnostic and therapeutic biomarkers of wild type gastrointestinal stromal tumours - Letter to the editor. Histopathology. 2015 Nov;67(5):746-7
  17. Saponara M, Pantaleo MA, Nannini M, Biasco G. Treatments for gastrointestinal stromal tumors that are resistant to standard therapies. Future Oncol. 2014 Oct;10(13):2045-59.
  18. Nannini M, Astolfi A, Urbini M, Indio V, Santini D, Heinrich MC, Corless CL, Ceccarelli C, Saponara M, Mandrioli A, Lolli C, Ercolani G, Brandi G, Biasco G, Pantaleo MA. Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). BMC Cancer 2014;14:685.
  19. Angelini S, Ravegnini G, Nannini M, Bermejo JL, Musti M, Pantaleo MA, Fumagalli E, Venturoli N, Palassini E, Consolini N, Casali PG, Biasco G, Hrelia P. Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. Eur J Hum Genet. 2015 Jun;23(6):817-23.
  20. Saponara M, Lolli C, Nannini M, DI Scioscio V, Serra C, Mandrioli A, Pallotti MC, Biasco G, Pantaleo MA. Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours. Oncol Lett 2014;8(4):1793-1799.
  21. Pantaleo MA, Lolli C, Nannini M, Astolfi A, Indio V, Saponara M, Urbini M, La Rovere S, Gill A, Goldstein D, Ceccarelli C, Santini D, Rossi G, Fiorentino M, Di Scioscio V, Fusaroli P, Mandrioli A, Gatto L, Catena F, Basso U, Ercolani G, Pinna AD, Biasco G. Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. Genet Med. 2015 May;17(5):391-5.
  22. Pantaleo MA, Nannini M, Corless CL, Heinrich MC. Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways. Cancer Med. 2015 Jan;4(1):101-3.
  23. Pantaleo MA, Astolfi A, Urbini M, Fuligni F, Saponara M, Nannini M, Lolli C, Indio V, Santini D, Ercolani G, Brandi G, Pinna AD, Biasco G. Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors. Clin Sarcoma Res. 2014;4:9.
  24. Nannini M, Astolfi A, Urbini M, Biasco G, Pantaleo MA. Liquid biopsy in gastrointestinal stromal tumors: a novel approach. J Transl Med. 2014;12:210.
  25. Pantaleo MA, Nannini M, Astolfi A, Biasco G. Novel Clinically Relevant Genes in GIST--Letter. Clin Cancer Res. 2014 Apr 1;20(7):2014
  26. Nannini M, Biasco G, Astolfi A, Urbini M, Pantaleo MA. Insulin-like Growth Factor (IGF) system and gastrointestinal stromal tumours (GIST): present and future. Histol Histopathol. 2014 Feb;29(2):167-75
  27. Nannini M, Astolfi A, Biasco G, Pantaleo MA. An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST). J Med Genetics 2013 Oct;50(10):653-61
  28. Nannini M, Pantaleo MA, Biasco G. Role of molecular analysis in the adjuvant treatment of gastrointestinal stromal tumours: it is time to define it. World J Gastroenterol. 2013;19:2583-6.
  29. Pantaleo MA, Astolfi A, Urbini M, Nannini M, Paterini P, Indio V, Saponara M, Formica S, Ceccarelli C, Casadio R, Rossi G, Bertolini F, Santini D, Pirini MG, Fiorentino M, Basso U, Biasco G. Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST. Eur J Hum 2014 Jan;22(1):32-9
  30. Pallotti MC, Pantaleo MA, Nannini M, Centofanti F, Fabbrizio B, Montanari M, Baraldi O, Saponara M, Lolli C, Mandrioli A, Biasco G, Prandini R. Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib. Case Rep Oncol 2012;5(3):651-6.
  31. Nannini M, Astolfi A, Paterini P, Urbini M, Santini D, Catena F, Indio V, Casadio R, Pinna AD, Biasco G, Pantaleo MA. Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction. Future Oncol. 2013 Jan;9(1):121-6.
  32. Catena F, Di Battista M, Ansaloni L, Pantaleo M, Fusaroli P, Di Scioscio V, Santini D, Nannini M, Saponara M, Ponti G, Persiani R, Delrio P, Coccolini F, Di Saverio S, Biasco G, Lazzareschi D, Pinna A. Microscopic margins of resection influence primary gastrointestinal stromal tumor survival. Onkologie. 2012;35(11):645-8.
  33. Angelini S, Pantaleo MA, Ravegnini G, Zenesini C, Cavrini G, Nannini M, Fumagalli E, Palassini E, Saponara M, Di Battista M, Casali PG, Hrelia P, Cantelli-Forti G, Biasco G. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. Pharmacol Res. 2012 Nov 2;68(1):1-6.
  34. Nannini M, Pantaleo MA, Catena F, Romano S, Tondo S, Pirini MG, Lolli C, Maleddu A, Mandrioli A, Gatto L, Saponara M, Pallotti MC, Dei Tos AP, Pinna AD, Biasco G. Surgical second-look in high risk gastrointestinal stromal tumor of small intestine: A case report. Int J Surg Case Rep. 2012 Sep 19;4(1):7-10.
  35. Nannini M, Pantaleo MA, Maleddu A, Saponara M, Mandrioli A, Lolli C, Pallotti MC, Gatto L, Santini D, Paterini P, DI Scioscio V, Catena F, Fusaroli P, Pinna AD, Tos AP, Biasco G. Duration of adjuvant treatment following radical resection of metastases from gastrointestinal stromal tumours. Oncol Lett. 2012;3:677-681.
  36. Pantaleo MA, Mandrioli A, Saponara M, Nannini M, Erente G, Lolli C, Biasco G. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer. 2012 Jun 11;12:231.
  37. Saponara M, Pantaleo MA, Nannini M, Biasco G. Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice. Target Oncol. 2012 Dec;7(4):243-6
  38. Lolli C, Pantaleo MA, Nannini M, Saponara M, Pallotti MC, Scioscio VD, Barbieri E, Mandrioli A, Biasco G. Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor. Rare Tumors 2011;3:e49.
  39. Pantaleo MA, Astolfi A, Nannini M, Ceccarelli C, Formica S, Santini D, Heinrich MC, Corless C, Dei Tos AP, Paterini P, Catena F, Maleddu A, Saponara M,Di Battista M, Biasco G. Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours. Histopathology 201159:1071-80.
  40. Pantaleo MA, Nannini M, Astolfi A, Biasco G; GIST Study Group Bologna. A distinct pediatric-type gastrointestinal stromal tumor in adults: potential role of succinate dehydrogenase subunit A mutations. Am J Surg Pathol 2011;35:1750-2

  41. Nannini M, Biasco G, Maleddu A, Pantaleo MA. New molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors (GISTs): present and future. Expert Opin Ther Targets. 2011 Jul;15(7):803-15.

  42. Nannini M, Pantaleo MA, Biasco G. The follow-up after radical surgery of colorectal cancer: is it time for a “tailored” strategy? Clin Colorectal Cancer 2011 Jun;10(2):81-4

  43. Nannini M, Biasco G, Pallotti MC, Di Battista M, Santini D, Paterini P, Maleddu A, Mandrioli A, Lolli C, Saponara M, Di Scioscio V, Zompatori M, Catena F, Fusaroli P, Dei Tos AP, Pantaleo MA. Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up. Med Oncol. 2012 Mar;29(1):144-50.
  44. Pantaleo MA, Nicoletti G, Nanni C, Gnocchi C, Landuzzi L, Quarta C, Boschi S, Nannini M, Di Battista M, Castellucci P, Fanti S, Lollini PL, Bellan E, Castelli M, Rubello D, Biasco G. Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. J Exp Clin Cancer Res. 2010 Dec 30;29:173

  45. Nannini M, Biasco G, Di Scioscio V, Di Battista M, Zompatori M, Catena F, Castellucci P, Paterini P, Dei Tos AP, Stella F, Maleddu A, Pantaleo MA. Clinical, radiological and biological features of lung metastases in gastrointestinal stromal tumors (case reports). Oncol Rep. 2011 Jan;25(1):113-20.

  46. Nannini M, Pantaleo MA, Paterini P, Piazzi G, Ceccarelli C, La Rovere S, Maleddu A, Biasco G. Molecular detection of epidermal growth factor receptor (EGFr) in colorectal cancer: does it still make sense? Colorectal Dis. 2011 May;13(5):542-8
  47. Pantaleo MA, Nannini M, Di Battista M, Catena F, Biasco G. Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy. Cancer Treat Rev. 2010 Feb;36(1):63-8.
  48. Di Cicilia R, Castellucci P, Nannini M, Balbi T, Zannetti G, Fanti S, Biasco G, Pantaleo MA. Unusual finding of benign Abrikossoff tumor by F-18 FDG-PET mimicking melanoma recurrence. Clin Nucl Med. 2009 Oct;34(10):696-7.
  49. Maleddu A, Pantaleo MA, Castellucci P, Astorino M, Nanni C, Nannini M, Busato F, Di Battista M, Farsad M, Lodi F, Boschi S, Fanti S, Biasco G. 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. Tumori. 2009 May-Jun;95(3):382-4.
  50. Pantaleo MA, Astolfi A, Nannini M, Biasco G. The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs). J Transl Med. 2010 Nov 15;8:117.
  51. Pantaleo MA, Di Battista M, La Rovere S, Astorino M, Catena F, Lolli C, Saponara M, Maleddu A, Nannini M, Di Scioscio V, Santini D, Ceccarelli C, Paterini P, Castellucci P, Astolfi A, Mandrioli A, Fusaroli P, Tomassetti P, Pinna AD, Biasco G. Management of patients with gastrointestinal stromal tumor in clinical practice in Italy: a critical "event tree model" analysis of decision-making processes and outcomes. Tumori. 2010 Mar-Apr;96(2):219-28.
  52. Astolfi A, Nannini M, Pantaleo MA, Di Battista M, Heinrich MC, Santini D, Catena F, Corless CL, Maleddu A, Saponara M, Lolli C, Di Scioscio V, Formica S, Biasco G. A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. Lab Invest. 2010 Sep;90(9):1285-94.
  53. Pantaleo MA, Nannini M, Di Battista M, Catena F, Biasco G. Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy. Cancer Treat Rev. 2010 Feb;36(1):63-8.
  54. Di Cicilia R, Castellucci P, Nannini M, Balbi T, Zannetti G, Fanti S, Biasco G, Pantaleo MA. Unusual finding of benign Abrikossoff tumor by F-18 FDG-PET mimicking melanoma recurrence. Clin Nucl Med. 2009 Oct;34(10):696-7.
  55. Maleddu A, Pantaleo MA, Castellucci P, Astorino M, Nanni C, Nannini M, Busato F, Di Battista M, Farsad M, Lodi F, Boschi S, Fanti S, Biasco G. 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. Tumori. 2009 May-Jun;95(3):382-4.
  56. Pantaleo MA, Astolfi A, Di Battista M, Heinrich MC, Paterini P, Scotlandi K, Santini D, Catena F, Manara MC, Nannini M, Maleddu A, Saponara M, Lolli C, Formica S, Biasco G. Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Int J Cancer. 2009 Dec 15;125(12):2991-4.
  57. Pantaleo MA, Nannini M, Fanti S, Boschi S, Lollini PL, Biasco G. Molecular imaging of EGFR: it's time to go beyond receptor expression. J Nucl Med. 2009 Jul;50(7):1195-6; author reply 1196, 1197.

  58. Nannini M, Nobili E, Di Cicilia R, Brandi G, Maleddu A, Pantaleo MA, Biasco G. To widen the setting of cancer patients who could benefit from metronomic capecitabine. Cancer Chemother Pharmacol. 2009 Jun;64(1):189-93.

  59. Nannini M, Pantaleo MA, Maleddu A, Astolfi A, Formica S, Biasco G. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev. 2009 May;35(3):201-9.
  60. Pantaleo MA, Nannini M, Maleddu A, Fanti S, Nanni C, Boschi S, Lodi F, Nicoletti G, Landuzzi L, Lollini PL, Biasco G. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Ann Oncol. 2009 Feb;20(2):213-26.
  61. Pantaleo MA, Astolfi A, Nannini M, Paterini P, Piazzi G, Ercolani G, Brandi G, Martinelli G, Pession A, Pinna AD, Biasco G. Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer. 2008 Nov 18;99(10):1729-34.
  62. Brandi G, Nannini M, Pantaleo MA, Fanello S, Farsad M, Fanti S, Ercolani G, Maleddu A, Di Battista M, Biasco G. Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients. Chemotherapy. 2008;54(6):421-4.
  63. Pantaleo MA, Nannini M, Lopci E, Castellucci P, Maleddu A, Lodi F, Nanni C, Allegri V, Astorino M, Brandi G, Di Battista M, Boschi S, Fanti S, Biasco G. Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases. Int J Oncol. 2008 Sep;33(3):443-52.
  64. Pantaleo MA, Fanti S, Nannini M, Boschi S, Nanni C, Maleddu A, Rubello D, Biasco G. What oncologists need and require from nuclear medicine. Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1761-5.
  65. Pantaleo MA, Nannini M, Maleddu A, Fanti S, Ambrosini V, Nanni C, Boschi S, Biasco G. Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Rev. 2008 Apr;34(2):103-21.
  66. Pantaleo MA, Saponara M, Nannini M, Biasco G. Targeted therapies in solid tumours: results and promises. Minerva Med. 2007 Oct;98(5):603-23. Review.


 

Ultimi avvisi

Al momento non sono presenti avvisi.